Loading...
XHKG
1763
Market cap700mUSD
Jul 09, Last price  
17.16HKD
1D
-2.17%
1Q
-14.11%
IPO
-22.35%
Name

China Isotope & Radiation Corp

Chart & Performance

D1W1MN
XHKG:1763 chart
P/E
14.90
P/S
0.68
EPS
1.00
Div Yield, %
2.48%
Shrs. gr., 5y
Rev. gr., 5y
10.37%
Revenues
7.00b
-7.57%
2,152,134,0002,363,122,0002,672,045,0003,238,019,0003,988,904,0004,274,183,0005,143,694,0006,146,172,0006,634,992,0007,574,756,0007,001,636,366
Net income
319m
-21.57%
254,205,000262,108,000271,454,000322,951,000329,030,000213,582,000335,751,000392,275,000370,967,000406,645,000318,950,877
CFO
538m
+277.83%
389,536,000457,633,000429,760,000577,710,000601,891,000291,913,000794,312,000862,659,00084,957,000142,481,000538,343,000
Dividend
Jun 23, 20260.289 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.
IPO date
Jul 06, 2018
Employees
3,264
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT